Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation details resulting from a dividend reinvestment plan.
- Share Price: 1,496.49 pence per Share.
- Transaction Type: Acquisition of Ordinary Shares via dividend reinvestment.
- Dividend Payment Date: April 14, 2016.
Material Changes
No material changes to financial performance or operational status are reported in this document. The filing details specific share allocations for the following individuals:
- Directors/PDMRs: Sir Andrew Witty (2,257.407 shares), Mr R Connor (552.391 shares), Mr S A Hussain (1,460.067 shares), Mr D S Redfern (2,129.312 shares), Dr M M Slaoui (4.719 shares), Ms C Thomas (2,692.384 shares), Mr P C Thomson (1,002.153 shares), Dr P J T Vallance (3,827.535 shares), and Ms E Walmsley (2,705.444 shares).
- Connected Persons: Mrs K Thomson (251.103 shares).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider share transactions and contains no forward-looking statements or risk assessments.
Investor Verification Points
- Verify the total number of shares acquired by directors and PDMRs through the dividend reinvestment program.
- Confirm the share price of 1,496.49 pence used for the April 14, 2016 dividend reinvestment.
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F or quarterly earnings releases for revenue and profit metrics.